List of Bioinformatics Companies in Washington - 22

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Advanced Cellular Dynamics (ACD) is a world-leader in the production, provision and application of novel cell-based assay systems. Our capabilities provide us with a unique capability to explore a variety of biological entities and systems. We have deep-rooted expertise in kinases, GPCRs, ion channels and transcription factors - to name a few. Those skills are applied to a variety of experimental systems that include (but aren't limited to) oncology, immunology and neurobiology. We also leverage these skills to provide our global clientele with contract research services. Whether you want to disrupt a specific gene in stem cells, or create a new biological cell-based assay in your tissue/cell line of choice, we have the knowledge and skills to help you succeed!

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Arzeda combines protein design, pathway design, HT screening and strain construction to create and improve designer fermentation strains for virtually any chemical. One example of their work is indeveloping new and improved enzymes to make rare sugars, natural sweeteners,and other oligosaccharides.

Cancer Research And Biostatistics (CRAB)® is a non-profit organization whose mission is to help conquer cancer, and other diseases. Since 1997, CRAB has supported over 300 clinical trials in partnership with foundations, universities, pharmaceutical and biotech companies. Past project experience has ranged from phase I to phase III, registration, staging, and prevention trials. CRAB provides a constellation of services that can help with concept creation, trial conduct, and regulatory submission or publication. Dr. Antje Hoering serves as President and CEO. Dr. John Crowley, co-founder with Dr. Cay Crowley, is Chairman of the Board of Directors. CRAB believes that collaboration accelerates outcomes. CRAB has long-standing partnerships with several cancer research organizations, including the SWOG Cancer Research Network, The Hope Foundation for Cancer Research, and SWOG Clinical Trials Partnerships. SWOG is one of five National Cancer Institute (NCI) supported members of the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP). CRAB and Fred Hutchinson Cancer Research Center make up the SWOG Statistics and Data Management Center (SDMC). CRAB is also an integral collaborator with the International Association for the Study of Lung Cancer (IASLC) since the late 1990s, publishing analysis for over 200,000 lung cancer cases in the 7th and 8th editions of the Staging Manuals. CRAB currently serves as the Independent Analysis Center for Friends of Cancer Research's ctDNA for Monitoring Treatment Response (ctMoniTR) Project. In this project, CRAB receives data from the pharmaceutical and diagnostic partners, coordinates input from collaborators, harmonizes and pools data, and analyzes the pooled data to meet the project's objectives. Message us to learn how we can support you in your next clinical trial, or partner with you, to continue to make strides in preventing and curing cancer.

Cyrus Biotechnology is a biotechnology company that specializes in protein engineering and drug discovery through computational biology.

Engineering and Design of Implantable Medical Devices We are the industry leader in Engineering and Design of implantable medical devices and have helped many companies through the product development and regulatory approval process. ECHOBIO LLC has over 18 years of experience with medical devices including self-expanding and balloon expandable stents, stent grafts, heart valves and others, as well as a strong background in implantable materials (metals, polymers, ceramics and biomaterials). This experience provides a solid foundation for using FEA and improves our simulation of devices and surgical procedures. We participate on international standards committees and pioneer innovative materials research to develop better engineering methods for making safe and reliable implantable medical devices. Our goal is to put our engineering and medical product expertise to work for customers and partners, helping them to move quickly and confidently to market with safe and effective products. From concept through design, development and regulatory approval, ECHOBIO LLC can help you create better products.

FenoLogicahelpsscientists gain insight into complex cellular interactions, creating a deeper understanding of human disease to improve patient outcomes. Our combined instrumentation and Cloud-based quantitative biology tools expedite the understanding of disease susceptibility and causation, leading to optimized therapeutic solutions.

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

The Institute for Disease Modeling (IDM) is part of the Bill & Melinda Gates Foundation's Global Health Division. IDM's goal is to support global efforts to eradicate infectious diseases and achieve permanent improvements in health by developing, using, and sharing computational modeling tools and promoting quantitative decision-making. Improving the health of all people, especially those in the most vulnerable populations, is a pressing and complex problem that engages diverse contributors, from health workers on the ground to funding agencies that provide resources and support. Data-driven approaches, including the development of dynamic models, statistical analysis, and the development and application of innovative algorithms, make fundamental contributions that inform primary research programs, intervention strategies, resource allocation, and other avenues of health care delivery.

Koidra is an intelligent automation company, dedicated to modernizing the automation of manufacturing facilities, with the high-tech greenhouse industry being the core market. Our tiered products deliver a comprehensive solution that enhances industrial efficiency.

Microsoft is a technology company that offers a wide range of software, cloud computing services, hardware, and artificial intelligence solutions.

Developing a single cell immunoprofiling platform.The company’s tools quantify and assess what types of cells are in samples based on the composition of surface proteins.

Pattern Computer, Inc., a Seattle-area AI & ML company, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems. As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major pattern discoveries for partners in other sectors, including biotech, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. Highlights: • Innovative / Proprietary Technology • Pattern Discovery Engine™ discovers and generates valuable hypotheses and insights into complex data, revealing novel patterns that cannot be discovered using conventional techniques or tools • Pattern produces exceptionally valuable assets within some of the most fiercely competitive domains … and commercializes them • Multiple high-growth markets: immediate focus most daunting yet immediate promise for life-changing & life-saving contributions to society including: • Life Sciences • XAI • Commercial Journey along with us as we move from creating our high-value assets to capitalization/commercialization of them- taking AI by storm with our focus on Third Wave AI.

Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software. Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.

Phenome Health is a research organization dedicated to preventing disease and taking the guesswork out of healthcare. We are driving a revolution by moving past the disease-focused “find it and fix it” era to wellness and prevention that enables all of us to live longer and healthier lives.

Sage Bionetworks is a trusted nonprofit leader in data sharing and reuse, enabling a rapid acceleration in biomedical discoveries and the transformation of medicine. Our mission is to drive a new age of discovery through truly open science and radical collaboration. Better Science Together.

Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

Sesh is committed to improving care for cancer patients. The newest paradigm in healthcare is precision medicine, whereby each patient is given the right treatment at the right time. This strategy leads to the best outcome. In oncology, there are many different types of treatment - from chemo, radiation, and surgery to targeted inhibitors and immunotherapy. Sesh operates at the forefront of medicine, applying a precision oncology approach to the newest and most promising type of cancer therapy, immunotherapy.Our technology, RELOAD, allows each cancer patient and their oncology team to determine whether immunotherapy is the optimal type of treatment at a given time. For many patients, immunotherapy is indeed the best option, but other patients may be unlikely to benefit from immunotherapy due to biomarkers that prevent immunotherapy from being effective. RELOAD measures the presence of these biomarkers, so that informed treatment decisions can be made. Making treatment decisions utilizing the information from RELOAD can save a patient's life.

Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs

Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. The company’s proprietary platform, powered by advanced machine learning, taps into uncharted chemical space to design de novo molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies. Vilya is leveraging its platform to focus on previously difficult-to-drug therapeutic targets. Vilya was co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners. The company has operations in Seattle and South San Francisco.

Yoneda Labs is an AI-based software company that assists chemists in optimizing reaction parameters such as temperature, concentration, and catalyst. The company's platform helps to figure out the reaction parameters without wet lab experimentation, and then can help optimize if necessary.